Establishment of an in vitro 3D model for neuroblastoma enables preclinical investigation of combined tumor-stroma drug targeting.
Animals
Antineoplastic Agents
/ pharmacology
Cancer-Associated Fibroblasts
/ metabolism
Cell Line
Cell Proliferation
/ drug effects
Cell Survival
/ drug effects
Cyclooxygenase 2
/ metabolism
Dinoprostone
/ metabolism
Disease Models, Animal
Drug Delivery Systems
/ methods
Drug Evaluation, Preclinical
/ methods
Female
Humans
Mice
Neovascularization, Pathologic
/ metabolism
Neuroblastoma
/ drug therapy
Prostaglandin-E Synthases
/ metabolism
PGE2
cancer
mPGES-1
microsomal prostaglandin E synthase-1
multicellular tumor spheroids
Journal
FASEB journal : official publication of the Federation of American Societies for Experimental Biology
ISSN: 1530-6860
Titre abrégé: FASEB J
Pays: United States
ID NLM: 8804484
Informations de publication
Date de publication:
08 2020
08 2020
Historique:
received:
23
03
2020
revised:
12
06
2020
accepted:
15
06
2020
pubmed:
6
7
2020
medline:
26
2
2021
entrez:
6
7
2020
Statut:
ppublish
Résumé
The majority of anti-cancer therapies target the proliferating tumor cells, while the tumor stroma, principally unaffected, survives, and provide a niche for surviving tumor cells. Combining tumor cell and stroma-targeting therapies thus have a potential to improve patient outcome. The neuroblastoma stroma contains cancer-associated fibroblasts expressing microsomal prostaglandin E synthase-1 (mPGES-1). mPGES-1-derived prostaglandin E
Identifiants
pubmed: 32623799
doi: 10.1096/fj.202000684R
doi:
Substances chimiques
Antineoplastic Agents
0
Cyclooxygenase 2
EC 1.14.99.1
Prostaglandin-E Synthases
EC 5.3.99.3
Dinoprostone
K7Q1JQR04M
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
11101-11114Informations de copyright
© 2020 The Authors. The FASEB Journal published by Wiley Periodicals LLC on behalf of Federation of American Societies for Experimental Biology.
Références
Bissell MJ, Radisky D. Putting tumours in context. Nat Rev Cancer. 2001;1:46-54.
Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144:646-674.
Pietras K, Östman A. Hallmarks of cancer: interactions with the tumor stroma. Exp Cell Res. 2010;316:1324-1331.
Correia AL, Bissell MJ. The tumor microenvironment is a dominant force in multidrug resistance. Drug Resist Updates. 2012;15:39-49.
Valkenburg KC, de Groot AE, Pienta KJ. Targeting the tumour stroma to improve cancer therapy. Nat Rev Clin Oncol. 2018;15:366-381.
Maris JM. Recent advances in neuroblastoma. N Engl J Med. 2010;362:2202-2211.
Matthay KK, Maris JM, Schleiermacher G, et al. Neuroblastoma. Nat Rev Dis Primers. 2016;2:Article 16078.
Esposito MR, Aveic S, Seydel A, Tonini GP. Neuroblastoma treatment in the post-genomic era. J Biomed Sci. 2017;24:14.
Borriello L, Seeger RC, Asgharzadeh S, DeClerck YA. More than the genes, the tumor microenvironment in neuroblastoma. Cancer Lett. 2015;380:304-314.
Zhang J, Liu JS. Tumor stroma as targets for cancer therapy. Pharmacol Ther. 2013;137:200-215.
Pai R, Soreghan BA, Szabo IL, Pavelka ML, Baatar D, Tarnawski AS. Prostaglandin E-2 directly promotes human colon cancer growth by triggering activation of ERK2, c-fos gene and cell proliferation. Gastroenterology. 2002;122:A240-A.
Rasmuson A, Kock A, Fuskevåg OM, et al. Autocrine prostaglandin E2 signaling promotes tumor cell survival and proliferation in childhood neuroblastoma. PLoS One. 2012;7:e29331.
Sheng HM, Shao JY, Dubois RN. Prostaglandin E-2 increases growth and invasiveness of colorectal carcinoma cells. Gastroenterology. 2001;120:A494-A.
Sheng H, Shao J, Morrow JD, Beauchamp RD, DuBois RN. Modulation of apoptosis and Bcl-2 expression by prostaglandin E2 in human colon cancer cells. Cancer Res. 1998;58:362-366.
Kalinski P. Regulation of immune responses by prostaglandin E2. J Immunol. 2012;188:21-28.
Zelenay S, van der Veen A, Böttcher J, et al. Cyclooxygenase-dependent tumor growth through evasion of immunity. Cell. 2015;162:1257-1270.
Fukuda R, Kelly B, Semenza GL. Vascular endothelial growth factor gene expression in colon cancer cells exposed to prostaglandin E2 is mediated by hypoxia-inducible factor 1. Cancer Res. 2003;63:2330-2334.
Pai R, Szabo IL, Soreghan BA, Atay S, Kawanaka H, Tarnawski AS. PGE(2) stimulates VEGF expression in endothelial cells via ERK2/JNK1 signaling pathways. Biochem Biophys Res Commun. 2001;286:923-928.
Buchanan FG, Wang D, Bargiacchi F, DuBois RN. Prostaglandin E2 regulates cell migration via the intracellular activation of the epidermal growth factor receptor. J Biol Chem. 2003;278:35451-35457.
Brocard E, Oizel K, Lalier L, et al. Radiation-induced PGE2 sustains human glioma cells growth and survival through EGF signaling. Oncotarget. 2015;6:6840-6849.
Kurtova AV, Xiao J, Mo Q, et al. Blocking PGE2-induced tumour repopulation abrogates bladder cancer chemoresistance. Nature. 2015;517:209-213.
Larsson K, Kock A, Idborg H, et al. COX/mPGES-1/PGE2 pathway depicts an inflammatory-dependent high-risk neuroblastoma subset. Proc Natl Acad Sci U S A. 2015;112:8070-8075.
Kock A, Larsson K, Bergqvist F, et al. Inhibition of microsomal prostaglandin E synthase-1 in cancer-associated fibroblasts suppresses neuroblastoma tumor growth. EBioMedicine. 2018;32:84-92.
Zanoni M, Piccinini F, Arienti C, et al. 3D tumor spheroid models for in vitro therapeutic screening: a systematic approach to enhance the biological relevance of data obtained. Sci Rep. 2016;6.
Leclerc P, Idborg H, Spahiu L, et al. Characterization of a human and murine mPGES-1 inhibitor and comparison to mPGES-1 genetic deletion in mouse models of inflammation. Prostaglandins Other Lipid Mediat. 2013;107:26-34.
Larsson K, Steinmetz J, Bergqvist F, et al. Biological characterization of new mPGES-1 inhibitors in preclinical models of inflammation and vascular tone. Br J Pharmacol. 2019;176(24):4625-4638.
Johnsen JI, Lindskog M, Ponthan F, et al. Cyclooxygenase-2 is expressed in neuroblastoma, and nonsteroidal anti-inflammatory drugs induce apoptosis and inhibit tumor growth in vivo. Cancer Res. 2004;64:7210-7215.
Kimlin LC, Casagrande G, Virador VM. In vitro three-dimensional (3D) models in cancer research: an update. Mol Carcinog. 2013;52:167-182.
Park JR, Bagatell R, London WB, et al. Children's Oncology Group's 2013 blueprint for research: neuroblastoma. Pediatr Blood Cancer. 2013;60:985-993.
Kenny HA, Lal-Nag M, White EA, et al. Quantitative high throughput screening using a primary human three-dimensional organotypic culture predicts in vivo efficacy. Nat Commun. 2015;6:6220.
Unger C, Kramer N, Walzl A, Scherzer M, Hengstschlager M, Dolznig H. Modeling human carcinomas: physiologically relevant 3D models to improve anti-cancer drug development. Adv Drug Deliv Rev. 2014;79-80:50-67.
Dvorak HF, Flier J, Frank H. Tumors-wounds that do not heal-similarities between tumor stroma generation and wound-healing. N Engl J Med. 1986;315:1650-1659.
Kalluri R. The biology and function of fibroblasts in cancer. Nat Rev Cancer. 2016;16:582-598.
Cortez E, Roswall P, Pietras K. Functional subsets of mesenchymal cell types in the tumor microenvironment. Semin Cancer Biol. 2014;25:3-9.
Ozen G, Gomez I, Daci A, et al. Inhibition of microsomal PGE synthase-1 reduces human vascular tone by increasing PGI2: a safer alternative to COX-2 inhibition. Br J Pharmacol. 2017.
Sasaki Y, Ochiai T, Takamura M, Kondo Y, Yokoyama C, Hara S. Role of prostacyclin synthase in carcinogenesis. Prostaglandins Other Lipid Mediat. 2017;133:49-52.
Bergqvist F, Ossipova E, Idborg H, et al. Inhibition of mPGES-1 or COX-2 results in different proteomic and lipidomic profiles in A549 lung cancer cells. Front Pharmacol. 2019;10:636.
Hangai S, Ao T, Kimura Y, et al. PGE2 induced in and released by dying cells functions as an inhibitory DAMP. Proc Natl Acad Sci USA. 2016;113:3844-3849.
Miyoshi H, VanDussen KL, Malvin NP, et al. Prostaglandin E2 promotes intestinal repair through an adaptive cellular response of the epithelium. EMBO J. 2017;36:5-24.
Huang Q, Li F, Liu X, et al. Caspase 3-mediated stimulation of tumor cell repopulation during cancer radiotherapy. Nat Med. 2011;17:860-866.
Greenhough A, Smartt HJ, Moore AE, et al. The COX-2/PGE2 pathway: key roles in the hallmarks of cancer and adaptation to the tumour microenvironment. Carcinogenesis. 2009;30:377-386.